: A Targeted Approach To Reduce Risk of Blood Clotting in MPN Patients Oct 1, 2023 - Sep 30, 2024 A new mechanism has been identified where an intracellular switch, called AMP-activated protein kinase (AMPK) inhibits the function of constitutively active JAK2V617F protein responsible for disease in many patients with MPNs. Based on this observati... Read More about : A Targeted Approach To Reduce Risk of Blood Clotting in MPN Patients.
PreclinHUPET2: Enabling Enhanced Preclinical Nuclear Imaging For The North Of England Feb 1, 2023 - Jan 31, 2024
SOCS VASC - Stabilising suppressor of cytokine signalling 3 (SOCS3) to limit vascular re-modelling in vein graft failure and in-stent restenosis Dec 1, 2019 - May 31, 2022
